Basin Energy (BSN:AU) has announced Basin Expands Geikie Athabasca Uranium Project
Download the PDF here.
This post appeared first on investingnews.com
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.
After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,243.7 as of March 31, 2025, further growth could be in store in the future.
According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.036 trillion.
Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.
The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.
Data was gathered on March 31, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.
1. Bright Minds Biosciences (NASDAQ:DRUG)
Company Profile
Year-over-year gain: 2,942.02 percent
Market cap: US$254.99 million
Share price: US$36.20
Bright Minds Biosciences is developing novel treatments for pain and neuropsychiatric disorders such as epilepsy, post-traumatic stress disorder and difficult-to-treat depression.The company’s platform includes serotonin agonists designed to provide powerful therapeutic benefits while minimizing side effects.
Bright Minds is currently in Phase 2 clinical trials for BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic absence epilepsy and developmental epileptic encephalopathy.
Bright Minds’ share price rocketed upward in the fourth quarter of last year, shooting up from US$2.49 to US$38.49 in one day on October 15. The company issued a press release at the time, stating it was ‘unaware of any material changes in the company’s operations’ that would have contributed to such a rally.
The outperformance appears to be related to the October 14 news that Danish pharma company H. Lundbeck was to acquire Longboard Pharma, a company developing a 5-HT2C receptor agonist, for US$60 per share.
A few days later, Bright Minds announced a non-brokered private placement of US$35 million, which sent shares up to US$47.21 on October 18.
That same month, the company shared its collaboration with Firefly Neuroscience (NASDAQ:AIFF) to use Firefly’s Brain Network Analytics technology platform to provide a full analysis of the electroencephalogram data from Bright Minds’ BMB-101 Phase 2 clinical trial. This follows the pair’s previous successful collaboration to analyze data from Bright Minds’ first-in-human Phase 1 study of BMB-101.
In March 2025, Bright Minds expanded its Scientific Advisory Board with the addition of five experts in epilepsy research.
Bright Minds’ share price reached US$55.77, its peak for the past year, on November 6.
2. Monopar Therapeutics (NASDAQ:MNPR)
Company Profile
Year-over-year gain: 924.54 percent
Market cap: US$220.3 million
Share price: US$36.10
Clinical-stage biotech Monopar Therapeutics’ main drug candidate is its late-stage ALXN-1840 for Wilson disease. Its pipeline also includes radiopharma programs such as Phase 1-stage MNPR-101-Zr for imaging advanced cancers, as well as Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers.
Shares in Monopar spiked by more than 600 percent on October 24, 2024, to US$32.66 following its news release detailing its exclusive worldwide licensing agreement with Alexion, AstraZeneca’s (NASDAQ:AZN) Rare Disease unit, for ALXN-1840, a drug candidate for Wilson disease that met its primary endpoints in its Phase 3 clinical trial. Going forward, Monopar will be responsible for all future global development and commercialization activities.
Further positive news flow in December continued to drive the company’s stock value. Early in the month, the company shared that the first patient was dosed with MNPR-101-Lu in its Phase 1a trial for the radiopharmaceutical. A few weeks later, Monopar announced the launch of a US$40 million concurrent public offering and private placement. After having fallen back to the US$22 range, shares in the company climbed to US$30.68 on December 17, 2024.
Positive sentiment in the company and the biotech market would later drive the stock up to its yearly high of US$51.89 on February 10, 2025. Monopar released its Q4 and full-year 2024 results on March 31.
3. Candel Therapeutics (NASDAQ:CADL)
Company Profile
Year-over-year gain: 268.3 percent
Market cap: US$262.39 million
Share price: US$5.64
Candel Therapeutics is a biotech company focused on developing oncology treatments. The company’s pipeline includes two clinical-stage multimodal biological immunotherapy platforms.
Candel’s lead product candidate, CAN-2409, is in a Phase 2 clinical trial in non-small cell lung cancer and borderline resectable pancreatic cancer, as well as Phase 2 and 3 trials for localized, non-metastatic prostate cancer.
The company had a number wins with the US Food and Drug Administration (FDA) in 2024. In February and May, respectively, Candel’s CAN-3110 received regulatory approval for fast-track designation and orphan drug designation for the treatment of recurrent high-grade glioma.
The agency also granted Candel orphan drug designation for CAN-2409 for the treatment of pancreatic cancer in April 2024. Positive interim data for the trial on pancreatic cancer released that month, sent the company’s share price spiking upward. It ultimately climbed to its 2024 high point of US$14.00 on May 15, 2024.
So far in 2025, Candel’s share price has traded as high as US$12.21 on February 20. In its January corporate update, the company shared its goals for the year, including aiming for Q4 for reporting overall survival data in patients with recurrent high-grade glioma from its ongoing phase 1b trial that is evaluating multiple doses of CAN-3110.
4. Tiziana Life Sciences (NASDAQ:TLSA)
Company Profile
Year-over-year gain: 154.76 percent
Market cap: US$119.51 million
Share price: US$1.08
Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous (IV) delivery. Tiziana’s lead candidate is intranasal foralumab, which it says is the only fully human anti-CD3 mAb currently in clinical development.
On May 31, 2024, shares in Tiziana broke above US$1 after a series of positive news flow for the company. This included positive clinical results from its intermediate sized Expanded Access Program for non-active secondary progressive multiple sclerosis patients, which demonstrated multiple improvements in foralumab-treated patients, as well as its submission of an orphan drug designation application to the FDA for intranasal foralumab for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS).
While Tiazana’s share price slid back down below US$1 per share by mid-June 2024, news that the FDA granted fast track designation to Tiziana intranasal foralumab for the treatment of na-SPMS gave it a much needed boost to the upside. By August 12, the stock’s value had risen to US$1.45 per share.
Tiziana Life Sciences shares reached a yearly peak of US$1.69 on March 7, 2025, after the company filed its investigational new drug application to the FDA for a phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association.
5. Benitec Biopharma (NASDAQ:BNTC)
Company Profile
Year-over-year gain: 149.71 percent
Market cap: US$331.43 million
Share price: US$13.01
California-based Benitec Biopharma is advancing novel genetic medicines via its proprietary “Silence and Replace” DNA-directed RNA interference platform. The company is currently focused on developing therapeutics for chronic and life-threatening conditions, including oculopharyngeal muscular dystrophy (OPMD).
Its drug candidate BB-301 was granted orphan drug designation by the FDA and the European Medicines Agency. Benitec is well funded to advance its BB-301 clinical development program through the end of 2025.
Benitec’s share price benefited from its first bump of the past year, after the company released its fiscal year Q3 2024 update in mid-May highlighting its achievements over the quarter. This included the closing of a US$40 million private placement. Benitec’s stock value hit US$10.47 per share on May 20, 2024.
Later in the fall, the company reported positive data from two patients with OPMD treated with low-dose BB-301 in phase 1b/2a study, showing the clinical trial is meeting key safety and efficacy endpoints. Shares hit another high of US$11.22 on October 17, 2024.
Benitec’s share price hit US$16.79, its highest yearly value to date, on March 20, 2025, a day after the company released positive interim clinical results for three patients with OPMD treated with BB-301 in phase 1b/2a study.
“The sixth and final Subject of Cohort 1 will be treated with BB-301 in the second calendar quarter of this year, and we are highly optimistic about the potential for continued benefit in Subjects enrolled in the ongoing clinical study,” said Jerel A. Banks, Benitec Executive Chairman and CEO.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
StrategX Elements Corp. (CSE: STGX) (‘StrategX’ or the ‘Company’) announces that Gary Wong has stepped down from his role as the Company’s Vice President of Exploration. While Gary is transitioning from this position, he will continue to contribute to other capacities, bringing his expertise and leadership to key projects. The Board would like to thank Gary for his efforts and contributions over the past two years.
About StrategX
StrategX is an exploration company focused on discovering critical metals in northern Canada. With projects on the East Arm of the Great Slave Lake (Northwest Territories) and the Melville Peninsula (Nunavut), the Company is pioneering new district-scale discoveries in these underexplored regions. By integrating historical data with modern exploration techniques, StrategX provides investors with a unique opportunity to participate in discovering essential metals crucial to electrification, global green energy, and supply chain security.
On Behalf of the Board of Directors
Darren G. Bahrey
CEO, President & Director
For further information, please contact:
StrategX Elements Corp.
info@strategXcorp.com
Phone: 604.379.5515
For further information about the Company, please visit our website at www.strategXcorp.com.
Neither the Canadian Securities Exchange nor its regulation services accept responsibility for the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.
Not for distribution to United States newswire services or for dissemination in the United States.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247050
News Provided by Newsfile via QuoteMedia
This post appeared first on investingnews.com
The gold price reached yet another record high on Monday (March 31), breaking US$3,100 per ounce.
The precious metal has gained significant momentum since the beginning of the year. In morning trading on Monday it surged past the US$3,100 mark, climbing as high as US$3,124.96.
Monday’s rise precedes US President Donald Trump’s planned retaliatory tariffs, which are set to come into effect on Wednesday (April 2). The new round is aimed at countries that have placed tariffs on US goods.
Gold price chart, March 24 to 31, 2025.
How widespread the tariffs will be, or if there will be any carve outs, is still unknown.
Trump has threatened various tariffs since the start of his administration, but few have yet to materialize. The majority have targeted US trade partners like Canada, Mexico and the European Union.
On March 26, Trump announced a 25 percent tariff on all automobiles made outside of the US, but suggested there may be exemptions for parts and vehicles that fall under US-Mexico-Canada Agreement guidelines. Those rules require that 60 percent of vehicles and components be manufactured in the US, Canada or Mexico.
The net effect of Trump’s actions has been political and financial turmoil, sparking selloffs on major stock markets and pushing prices for safe-haven assets like gold to fresh records.
Additionally, China, Japan and South Korea agreed on Sunday (March 30) to seek deeper free trade ties in response to the threat of tariffs from the US government. The deal marks a significant move by the three countries following decades of US diplomacy to maintain close relationships with Japan and South Korea.
Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Here’s a quick recap of the crypto landscape for Monday (March 31) as of 9:00 p.m. UTC.
Bitcoin and Ethereum price update
At the time of this writing, Bitcoin (BTC) was changing hands at US$82,583.58. The day’s range has brought a low of US$81,709.73 and a high of US$83,757.45.
Bitcoin performance, March 31, 2025.
Chart via TradingView.
The cryptocurrency is staging a modest recovery ahead of US President Donald Trump’s sweeping tariffs policy, which is set to go into effect on Wednesday (April 2).
Ethereum (ETH) is priced at US$1,828.36, a 0.7 percent increase over 24 hours. The cryptocurrency reached an intraday low of US$1,802.46 and a high of US$1,848.44.
Altcoin price update
- Solana (SOL) is currently valued at US$125.35, down 0.3 percent over the past 24 hours. SOL experienced a low of US$123.65 and a high of US$127.50 on Monday.
- XRP is trading at US$2.09, reflecting a 2.2 percent decrease over the past 24 hours. The cryptocurrency recorded an intraday low of US$2.07 and a high of US$2.13.
- Sui (SUI) is priced at US$2.27, showing a 3.4 percent decrease over the past 24 hours. It achieved a daily low of US$2.20 and a high of US$2.30.
- Cardano (ADA) is trading at US$0.6555, reflecting a 1.7 percent decrease over the past 24 hours. Its lowest price on Friday was US$0.6379, with a high of US$0.6637.
Crypto news to know
Saylor’s Strategy adds to Bitcoin holdings
Strategy (NASDAQ:MSTR), formerly MicroStrategy, added to its Bitcoin stockpile over the weekend with a purchase of 22,048 Bitcoin for US$1.92 billion, an average price of US$86,969 per Bitcoin.
According to a post from CEO Michael Saylor, the company had seen an 11 percent increase in the overall value of its Bitcoin holdings year-to-date as of March 30 (Sunday). The company’s Bitcoin holdings now total 528,185 Bitcoin, acquired for US$35.63 billion at an average price of US$67,458 each.
Metaplanet issues bonds to buy Bitcoin
Taking a page from Strategy’s playbook, Metaplanet (OTCQX:MTPLF,TSE:3350), a Japanese investment and asset management firm focused on real estate and technology ventures, has issued 2 billion yen in convertible bonds redeemable by September 30, 2025, aiming to capitalize on Bitcoin’s price decline.
Metaplanet is Asia’s largest corporate Bitcoin holder, with roughly 3,200 Bitcoin in its reserves worth approximately US$1.23 billion. The company’s CEO, Simon Gerovich, wrote on Monday that the firm is taking advantage of Bitcoin’s recent downturn, with proceeds from the sale earmarked for further Bitcoin purchases.
According to data from BitBo, an additional acquisition would mark the firm’s fourth Bitcoin purchase this month. Metaplanet acquired 497 Bitcoin on March 4, 162 Bitcoin on March 11 and 300 Bitcoin on March 24.
Hut 8 and American Bitcoin announce partnership
Hut 8 (NASDAQ:HUT), a Bitcoin-mining and digital infrastructure company, announced a deal with American Bitcoin on Monday. Under the terms of the agreement, American Bitcoin, a firm founded by a group of investors that includes Donald Trump Jr. and Eric Trump, will take ownership of Hut 8’s Bitcoin-mining hardware.
The partnership will form a new subsidiary “focused exclusively on industrial-scale Bitcoin mining and strategic Bitcoin reserve development,” with Hut 8 controlling a majority stake.
“The launch of American Bitcoin marks a pivotal evolution in our platform strategy,” said Asher Genoot, CEO of Hut 8, in a press release. “By carving out our mining business into a standalone entity, which will raise its own capital, we align each segment of the business with its respective cost of capital. The transaction creates two focused yet complementary businesses, each purpose-built for its respective mandate.”
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Inca Minerals (ICG:AU) has announced Inca to Raise $1.1M
Download the PDF here.
This post appeared first on investingnews.com
Cardiex Limited (CDX:AU) has announced CONNEQT Launches Apple Health Integration on iPhone
Download the PDF here.
This post appeared first on investingnews.com
Calls for mass purchases of silver on Monday (March 31) are gaining traction online, with proponents hoping to disrupt the dominance of major financial institutions in the precious metals market.
The movement appears to have originated from a March 22 post on X, formerly Twitter, made by user @TheSqueakyMouse, who urged their followers to band together to buy silver.
March 31st, BUY SILVERLets take back price control and break the banks. Spread the word; who’s in. #silversqueeze pic.twitter.com/bLl0hk725D
— Sqeaky Mouse (@TheSqeakyMouse) March 22, 2025
The message quickly gained momentum, particularly after being amplified by analyst Jesse Colombo.
Colombo, who posts on X under the handle @TheBubbleBubble, has been vocal about what he claims is a longstanding suppression of the silver price by large financial institutions.
‘Bullion banks like JPMorgan and UBS suppress silver prices through aggressive naked shorting — but a coordinated surge of physical buying could catch them off guard and break their hold on the market,’ he wrote on Substack.
Colombo and other supporters argue that financial institutions are suppressing silver prices through ‘naked shorting,’ a practice where banks take short positions on silver futures. He explained in his post that major banks currently hold net short positions of 44,583 silver futures contracts, equating to 223 million ounces of silver.
This means that for every US$1 increase in silver’s price, these institutions could face US$223 million in losses.
By encouraging retail investors to purchase physical silver, the movement hopes to exert upward pressure on the price, potentially forcing banks to cover their short positions, leading to a short squeeze scenario.
Echoes of the 2021 silver squeeze
This is not the first time retail investors have attempted to challenge institutional short positions in silver.
The original silver squeeze in early 2021 followed the high-profile GameStop (NYSE:GME) short squeeze, where retail traders from the Reddit forum WallStreetBets successfully drove up GameStop’s share price, triggering massive losses for hedge funds. Social media users then set their sights on silver, hoping to create a similar outcome.
Although the enthusiasm pushed silver above US$30, the movement ultimately lost momentum.
‘Honestly, I don’t think it’s going to have that much of an effect this time … The retail market in silver is languishing. One major wholesaler even had net negative demand, meaning more sells than buys, in the last couple of weeks.’
Morgan also pointed out that the first silver squeeze benefited from a perfect storm of retail enthusiasm, a low silver price and a post-GameStop wave of anti-Wall Street sentiment. This time, he believes, momentum is weaker, with higher prices and declining retail interest in silver compared to previous years.
Market reactions and price movements
The silver price stayed relatively steady ahead of Monday, with some minor upticks.
One key factor to watch will be the demand for physical silver versus paper silver (such as futures contracts or silver exchange-traded funds). If enough investors opt for physical bullion — rather than financial instruments that may not require actual silver delivery — it could create supply constraints that drive the metal higher.
Whether the Silver Squeeze 2.0 succeeds in significantly impacting the silver market remains to be seen. Whatever the result, the movement has reignited discussions about potential price suppression in the precious metals market and raised awareness about how retail investors can influence commodity markets.
The white metal reached a high of US$34.40 on Monday.
As of 2:55 p.m EST the silver price was holding in the US$34.03 range, marking a 3 percent uptick over the last five days and a 16.34 percent increase since the start of 2025.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Quimbaya Gold Inc. (CSE: QIM) (OTCQB: QIMGF) (FSE: K05) (‘Quimbaya Gold’ or the ‘Company’) is pleased to announce that shareholders voted to approve all items of business put forth to shareholders at the Company’s Annual General and Special Meeting (‘AGSM’) held on March 28, 2025, including the election of directors, fixing the number of directors, appointment of the Company’s auditor, approval of the equity incentive plan, and the continuation of the Company under the British Columbia Business Corporations Act.
The board of directors and the Company would like to thank Mr. Bayona, who did not run for re-election, for his service to the Company and would like to wish him well in his future endeavors.
Additionally, at the AGSM, Sebastian Wahl was elected as new independent director of the Company. Sebastian Wahl brings over 15 years of experience in the mining industry, specializing in precious metals trading and corporate development. As a co-founder and former Vice President of Corporate Development at Silver X Mining Corp., he played a pivotal role in consolidating assets and advancing projects in South America. Mr. Wahl holds a B.Sc. in Business Administration from the Graduate School of Business Administration in Zurich and a Financial Modelling certification from the Corporate Finance Institute. Fluent in Spanish, he possesses extensive expertise in South American mining operations and capital markets.
Mr. Alexandre P. Boivin, President & CEO stated, ‘We are excited to bring Sebastian on as an independent board member. His strong experience in South America and European connections will complement the Company as we strive to become an established player in the Colombian mining exploration space.’
About Quimbaya
Quimbaya aims to discover gold resources through exploration and acquisition of mining properties in the prolific mining districts of Colombia. Managed by an experienced team in the mining sector, Quimbaya is focused on three projects in the regions of Segovia (Tahami Project), Puerto Berrio (Berrio Project), and Abejorral (Maitamac Project), all located in Antioquia Province, Colombia.
Contact Information
Alexandre P. Boivin, President and CEO apboivin@quimbayagold.com
Jason Frame, Manager of Communications jason.frame@quimbayagold.com
Quimbaya Gold Inc.
Follow on X @quimbayagoldinc
Follow on LinkedIn @quimbayagold
Follow on Instagram @quimbayagoldinc
Follow on Facebook @quimbayagoldinc
Cautionary Statements
Certain statements contained in this press release constitute ‘forward-looking information’ as that term is defined in applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as ‘intends’, ‘expects’ or ‘anticipates’, or variations of such words and phrases or statements that certain actions, events or results ‘may’, ‘could’, ‘should’, ‘would’ or ‘occur’. Forward-looking information by its nature is based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Quimbaya to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Although Quimbaya’s management believes that the assumptions made and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Furthermore, should one or more of the risks, uncertainties or other factors materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Readers are cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Quimbaya as of the date of this news release and, accordingly, is subject to change after such date. Except as required by law, Quimbaya does not expect to update forward-looking statements and information continually as conditions change.
Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246745
News Provided by Newsfile via QuoteMedia
This post appeared first on investingnews.com
Brazil-focused explorer Alvo Minerals (ASX:ALV,OTC Pink:ALVMF) has signed a non-binding letter of intent with Pan American Silver (TSX:PAAS,NYSE:PAAS) to acquire the Lavra Velha gold-copper project.
According to Alvo, the project and surrounding exploration ground were considered by Pan American to be ‘non-core’ after the company completed its acquisition of Yamana Gold in 2022.
Mineralization was discovered at Lavra Velha in 2010, and the site was explored from 2010 to 2013, and then from 2018 to 2022. The project covers 55,000 hectares in Brazil’s Bahia state.
Lavra Velha has a NI 43-101 resource estimate of 9.2 million tonnes at 1.76 grams per tonne (g/t) gold for 520,000 ounces. That includes an indicated resource of 4.5 million tonnes at 1.96 g/t gold for 282,000 ounces, as well as an inferred resource of 4.7 million tonnes at 1.56 g/t gold for 238,000 ounces.
“We are very excited about the proposed acquisition of the Lavra Velha Gold-Copper Project,’ Alvo Managing Director Rob Smakman said in a Monday (March 31) announcement, adding that the property is complementary to the company’s Palma copper-zinc project. He also commented positively on current gold and copper market dynamics.
The company plans to update Lavra Velha’s NI 43-101 resource to meet JORC standards. Among other adjustments, it will use the current gold price instead of the previous US$1,650 per ounce price.
As part of the acquisition plan, Alvo will be opening an entitlement offer to raise up to AU$3.5 million among its shareholders, with each share priced at AU$0.06. Once raised, the amount is proposed to cover the US$1 million upfront cash payment portion of the transaction, along with initial exploration of Lavra Velha.
The entitlement offer is set to open to eligible Alvo shareholders on Friday (April 4).
Completion of the transaction with Pan American is subject to Alvo’s satisfaction of due diligence and the execution of an asset purchase agreement. The due diligence completion has a 45 day exclusivity period.
Shares of Alvo rose as high as AU$0.066 following the announcement, up 10 percent from the firm’s previous AU$0.06 close. Pan American finished at US$25.55, a 1.47 percent dip from its US$25.94 close last week.
According to Global Business Reports’ Brazil Mining 2024 report, mining in Brazil continues to be fueled by iron ore, but is slowly seeing diversification through a growing number of gold, rare earths and lithium projects.
Securities Disclosure: I, Gabrielle de la Cruz, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com